Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
38
GZPHF Quote, Financials, Valuation and Earnings
Last price:
$2.34
Seasonality move
:
-4.8%
Day range:
$2.34 - $2.34
52-week range:
$2.14 - $2.64
Dividend yield:
7.22%
P/E ratio:
9.25x
P/S ratio:
0.35x
P/B ratio:
0.70x
Volume:
--
Avg. volume:
--
1-year change:
-1.27%
Market cap:
$3.8B
Revenue:
$10.8B
EPS (TTM):
$0.25
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. has -- downside to fair value with a price target of -- per share.
GZPHF vs. S&P 500
-
Over the past 5 trading days, Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. reported revenues of $2.3B.
Earnings Growth
-
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. reported earnings per share of -$0.03.
Enterprise value:
3.7B
EV / Invested capital:
--
Price / LTM sales:
0.35x
EV / EBIT:
8.66x
EV / Revenue:
0.34x
PEG ratio (5yr expected):
2.14x
EV / Free cash flow:
-26.68x
Price / Operating cash flow:
18.40x
Enterprise value / EBITDA:
6.60x
Gross Profit (TTM):
$1.7B
Return On Assets:
3.67%
Net Income Margin (TTM):
3.92%
Return On Equity:
7.66%
Return On Invested Capital:
5.1%
Operating Margin:
-4.57%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $10.6B | $10.4B | $10.8B | $2.2B | $2.3B | |
| Gross Profit | $1.9B | $1.6B | $1.7B | $263.6M | $226.5M | |
| Operating Income | $636.2M | $411.7M | $425.6M | -$83.2M | -$103.5M | |
| EBITDA | $775.6M | $541.7M | $558.6M | -$51.6M | -$69.9M | |
| Diluted EPS | $0.36 | $0.24 | $0.25 | -$0.03 | -$0.03 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.3B | $8.2B | $7.9B | $7.9B | $8.8B | |
| Total Assets | $10.4B | $10.7B | $11.1B | $11.2B | $12.1B | |
| Current Liabilities | $5.1B | $5.4B | $5.1B | $5.3B | $5.6B | |
| Total Liabilities | $5.3B | $5.8B | $5.8B | $5.9B | $6.2B | |
| Total Equity | $4.9B | $4.8B | $5.2B | $5.2B | $5.7B | |
| Total Debt | $234.8M | $416M | $585.4M | $654M | $823.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $620.8M | $509.7M | $36.7M | $598.8M | $258.1M | |
| Cash From Investing | -$480.6M | -$856.5M | -$551.4M | -$255.7M | -$40.3M | |
| Cash From Financing | -$276.4M | -$142.1M | -$14.2M | -$219.4M | -$133.8M | |
| Free Cash Flow | $395.9M | $353M | -$138.2M | $555.1M | $210.2M | |
GZPHF
Sector
Market Cap
$3.8B
$23.9M
Price % of 52-Week High
88.64%
47.44%
Dividend Yield
7.22%
0%
Shareholder Yield
5.35%
-1.88%
1-Year Price Total Return
-1.27%
-18.29%
Beta (5-Year)
0.234
0.513
Dividend yield:
7.22%
Annualized payout:
$0.11
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.34
200-day SMA
Buy
Level
$2.31
Bollinger Bands (100)
Buy
Level
2.22 - 2.38
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$2.34
Relative Strength Index (RSI14)
Buy
Level
82.57
ADX Line
Neutral
Level
Williams %R
Sell
Level
0
50-day SMA
Sell
Level
$2.34
MACD (12, 26)
Buy
Level
0.52
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
--
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.0502)
Buy
CA Score
(Annual)
Level (-0.1941)
Sell
Beneish M-Score
(Annual)
Level (-2.2038)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.8992)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. engages in the manufacture, wholesale, retail, import, and export of pharmaceutical products, medical apparatus, and Chinese medicine. It operates in the following segments: Great Southern Traditional Chinese Medicine (TCM), Great Health, Great Commerce, and Other. The Great Southern TCM segment provides research, development, manufacturing, and sales for Chinese and Western medicine. The Great Health segment refers to the research, development, manufacturing, and sales for the products of Great Health. The Great Commerce segment relates to the wholesale, retail, import, and export for Western medicine, Chinese medicine, and medical apparatus and instruments. The Other segment is involved in other manufacturing and distributing traditional Chinese medicines activities. The company was founded on September 1, 1997 and is headquartered in Guangzhou, China.
Stock Forecast FAQ
In the current month, GZPHF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GZPHF average analyst price target in the past 3 months is --.
-
Where Will Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.?
Analysts are divided on their view about Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.'s Price Target?
The price target for Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GZPHF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of GZPHF?
You can purchase shares of Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. shares.
-
What Is The Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Share Price Today?
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. was last trading at $2.34 per share. This represents the most recent stock quote for Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.. Yesterday, Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. closed at $2.34 per share.
-
How To Buy Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Stock Online?
In order to purchase Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GZPHF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GZPHF
Sector
P/E ratio
9.25x
21.37x
PEG ratio
2.14x
-0.01x
P/B ratio
0.70x
1.72x
Price / LTM sales
0.35x
1.45x
Growth Metrics
GZPHF
Sector
Revenue growth
2.14%
3.44%
Earnings growth
-2.53%
15.03%
Revenue (5-year growth)
3.9%
6.25%
Earnings forecast
--
-$0.22
Profitability
GZPHF
Sector
Profitability FY 2025
$1.6B
$2.4M
Return on invested capital
5.1%
-33.32%
Return on assets
3.67%
-29.45%
Return on equity
7.66%
-40.29%
Earnings Date
Last Earnings Date
Apr
4
Next Earnings Date
Apr
4
Estimated Next Earnings Date
Jul
4
Balance Sheet
GZPHF
Sector
Total cash
$3.4B
$25.7M
Short term investments
$564.3K
$22.7M
Total assets
$12.1B
$70.6M
Long term debt
$823.8M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
